Navigation Links
Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Date:9/3/2009

lse rate, and ECG parameters were observed.

Important Safety Information

INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17. Efficacy was established in two controlled clinical trials (8 and 9 weeks in duration). The physician electing to use INTUNIV for extended periods should periodically reevaluate its long-term usefulness for the individual patient.

INTUNIV should not be used in patients with a history of hypersensitivity to guanfacine or any of its inactive ingredients or by patients taking other products containing guanfacine

Hypotension, bradycardia, and syncope were observed in clinical trials. Use INTUNIV with caution in treating patients who have experienced hypotension, bradycardia, heart block, or syncope, or who may have a condition that predisposes them to syncope; are treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope. Heart rate and blood pressure should be measured prior to initiation of therapy, following dose increases, and periodically while on therapy. Patients should be advised to avoid becoming dehydrated or overheated.

Sedation and somnolence were commonly observed in clinical trials. The potential for additive sedative effects with CNS depressant drugs should be considered. Patients should be cautioned against operating heavy equipment or driving until they know how they respond to INTUNIV.

Common adverse reactions in patients taking INTUNIV that may be dose-related over the range of 1 to 4 mg/day include somnolence, sedation, abdominal pain, dizziness, hypotension/decreased blood pressure, dry mouth, and constipation.

About ADHD

ADHD is one of the most common psychiatric disorders in children and adolescents. Worldwide prevalence of ADHD is estima
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Intelomed is pleased to announce that ... as the Vice President of Clinical Affairs. With over ... device industry, Kay,s experience in taking medical technology and ... to global expansion, is a valuable addition to the ... on our team, and I am confident her focused ...
(Date:8/26/2014)... Research and Markets has announced ... Report 2014 " report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of the industry ... glucose meter market analysis is provided for both the ...
(Date:8/26/2014)... DUBLIN , Aug. 26, 2014 ... "Global Intranasal Drug Delivery Market 2014-2018" report ... is a medical device used for the administration of ... nose and paranasal sinus such as allergic and non-allergic ... an ideal administrative route for needle-free vaccination and systematic ...
Breaking Medicine Technology:Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2Global Glucose Meter Industry Report 2014 2Global Glucose Meter Industry Report 2014 3Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
(Date:8/27/2014)... 2014 Aspirus Wausau Hospital today announced ... with Buzz™ Digital O.R. at Aspirus Wausau Hospital, in ... new operating rooms will be Buzz, a centralized surgical ... system supports planning, navigation, imaging and communications connectivity. ... intuitive software and hardware all controlled from the full ...
(Date:8/27/2014)... 26, 2014 (HealthDay News) -- Health care workers in ... to keep them safe from being infected with blood-borne ... shows. While the study was conducted before the ... its findings are confirmed in statistics released Monday by ... agency reported that an "unprecedented" number of health care ...
(Date:8/27/2014)... patients are 70 per cent more likely to continue ... they have a prescription in hand when discharged ... the Institute for Clinical Evaluative Sciences (ICES). , Using ... Ontarians were taking their medications one week, one year ... reveal the importance of simple interventions, such as giving ...
(Date:8/27/2014)... Hills, CA (PRWEB) August 27, 2014 Bedros ... camp franchise in the world, the leading fitness boot ... Spike TV’s Gym Rescue reality series. One thing he knows ... brand as a subject matter expert in the fitness business. ... to YouTube, he lays out a step-by-step instructional guide on ...
(Date:8/27/2014)... Phoenix, AZ (PRWEB) August 27, 2014 ... that serves the greater Phoenix metropolitan area and all ... client more than $160,000 on a $2 million settlement. ... tangible savings to those who have been injured through ... can be complex and time-consuming, however Hastings and Hastings ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:A prescription for better stroke care 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $166,700 On A Settlement Of $2,000,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $166,700 On A Settlement Of $2,000,000 3
... has been released by Australian obesity experts that show gastric ... conference on obesity in Sydney there were three studies which ... in mortality rates in obese people who had the surgery. ... upper part of the stomach for the procedure to restrict ...
... a 4- to 5-point IQ advantage over women by adulthood. ... to 18-year-//olds on the Scholastic Assessment Test (SAT). ... because girls mature faster than boys. This is the reason ... ,145 items from the SAT were examined by a study ...
... of the opinion that eating nuts about twice a week might ... that was presented at the World Congress of Cardiology stated that ... would be around a small plate full might reduce the risk ... survey confirmed that eating a small quantity of the same kinds ...
... hang heavy with heart problems, going back at least two ... she hit age 50,// Catherine got nervous. ,A ... and perhaps those of others in her family tree. She ... causes her heart muscle to grow too thick. The extra ...
... Industry in China has placed on record the successful initial ... vaccine is said to operate in low doses, nearly one-third ... undertaken till date. The smaller doses are proven to be ... observed that just two 10-microgram doses of the Sinovac vaccine, ...
... Scottish Executive have announced their plans to offer dental students ... them in the NHS.// ,It has been explained ... given ?4,000 a year in return for a commitment of ... ,Lewis Macdonald, the deputy health minister, had announced the launch ...
Cached Medicine News:Health News:Greater g factor in men responsible for sex differences in general mental ability 2Health News:Greater g factor in men responsible for sex differences in general mental ability 3Health News:Fight Back Against Inherited Sudden-Death Heart Condition 2Health News:Fight Back Against Inherited Sudden-Death Heart Condition 3Health News:Fight Back Against Inherited Sudden-Death Heart Condition 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: